Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric Subjects with Primary Immunodeficiency Diseases
Phase of Trial: Phase IV
Latest Information Update: 21 Oct 2017
At a glance
- Drugs Immune globulin (Primary) ; Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Adverse reactions
- Sponsors Shire
- 11 Oct 2017 Status changed from not yet recruiting to recruiting.
- 24 May 2017 Planned initiation date changed from 30 Apr 2017 to 15 Jun 2017.
- 05 Apr 2017 New trial record